Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT1 | P04628 | 10/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.44 |
| ▸ | CLK2 | P49760 | 6/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.40 |
| ▸ | CLK3 | P49761 | 4/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17564224 | 0.94 | WNT1 (0.51) | WNT1TGFBR1CYP17A1CLK2DYRK1A | |
| SCHEMBL17564196 | 0.91 | CLK2 (0.43) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17564120 | 0.90 | WNT1 (0.45) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17639314 | 0.89 | WNT1 (0.51) | WNT1TGFBR1CYP17A1CLK2DYRK1A | |
| SCHEMBL17564403 | 0.88 | WNT1 (0.42) | WNT1TGFBR1CYP17A1CLK2DYRK1A | |
| SCHEMBL17564371 | 0.88 | WNT1 (0.55) | WNT1TGFBR1CYP17A1CLK2DYRK1A | |
| SCHEMBL17569244 | 0.87 | CLK2 (0.51) | WNT1TGFBR1CYP17A1CLK2DYRK1A | |
| SCHEMBL17564158 | 0.87 | WNT1 (0.41) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17564140 | 0.87 | WNT1 (0.42) | WNT1TGFBR1CLK2DYRK1ACLK3 | |
| SCHEMBL17564161 | 0.87 | WNT1 (0.48) | WNT1TGFBR1CLK2DYRK1ACLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-04-25 | — | — | US | disclosed |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
| US-9758531-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758531-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 339/4885CYP17A1 2978/4885 |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 339/4885CYP17A1 2978/4885 |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | WNT1 1/4885TGFBR1 339/4885CYP17A1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.